Thomas R. Blue

Dr. Thomas Blue Receives Promotion to Senior Research Scientist

FRI is pleased to announce that Dr. Thomas R. Blue has been promoted from Research Scientist to Senior Research Scientist, effective September 20, 2024. Dr. Blue joined FRI in September of 2017. Since that time, he has served as a Principal Investigator (PI), Multiple Principal Investigator (MPI), or Co-Investigator on a number of studies conducted at FRI. Initially, he served as the site PI on a National Institute on Drug Abuse (NIDA) funded administrative supplement to a HEAL – JCOIN award, “A comparison of sublingual and extended-release buprenorphine for individuals leaving jail.” Currently, he serves as an MPI on a NIDA funded study “A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting,” which builds on the investigators’ experience conducting clinical trials using both extended-release buprenorphine (XR-B) and sublingual-buprenorphine-naloxone (SL-B) with individuals in jails and prisons. Dr. Blue also serves as an MPI on a NIDA funded study through the HEAL initiative “A comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.” Dr. Blue is also a Co-Investigator/Statistician on two additional NIDA funded studies, “NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings” and “Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression.

FRI would like to congratulate Dr. Blue on these notable achievements and wishes him continued success in his research career at FRI.